Search results
Results from the WOW.Com Content Network
Following infection with HIV, the rate of clinical disease progression varies enormously between individuals. Many factors such as host susceptibility and immune function, [2] [3] [4] health care and co-infections, [5] [6] [7] as well as factors relating to the viral strain [8] [9] may affect the rate of clinical disease progression.
WHO Disease Staging System for HIV Infection and Disease was first produced in 1990 by the World Health Organization [1] and updated in 2007. [2] It is an approach for use in resource limited settings and is widely used in Africa and Asia and has been a useful research tool in studies of progression to symptomatic HIV disease .
The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources.
Since opportunistic infections can cause severe disease, much emphasis is placed on measures to prevent infection. Such a strategy usually includes restoration of the immune system as soon as possible, avoiding exposures to infectious agents, and using antimicrobial medications ("prophylactic medications") directed against specific infections.
In 1993, the CDC added pulmonary tuberculosis, recurrent pneumonia and invasive cervical cancer [2] to the list of clinical conditions in the AIDS surveillance case definition published in 1987 [3] and expanded the AIDS surveillance case definition to include all HIV-infected persons with CD4+ T-lymphocyte counts of fewer than 200 cells/μL or ...
Although there was known to have been at least one case of AIDS in the U.S. from 1966, [269] the vast majority of infections occurring outside sub-Saharan Africa (including the U.S.) can be traced back to a single unknown individual who became infected with HIV in Haiti and brought the infection to the U.S. at some time around 1969. [252]
The ChemDB HIV, Opportunistic Infection and Tuberculosis Therapeutics Database is a publicly available tool developed by the National Institute of Allergy and Infectious Diseases to compile preclinical data on small molecules with potential therapeutic action against HIV/AIDS and related opportunistic infections.
Additionally, people with AIDS often have systemic symptoms of infection like fevers, sweats (particularly at night), swollen glands, chills, weakness, and weight loss. [13] [14] The specific opportunistic infections that AIDS patients develop depend in part on the prevalence of these infections in the geographic area in which the patient lives.